Introduction and Objectives Nintedanib and pirfenidone are licensed anti-fibrotic therapies (AFT) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). 1 Drug discontinuation rates in clinical trials were significant due to many side effects including weight loss. We aimed to establish average weight loss at 12 months in a group of patients commenced on AFT. Methods This was a retrospective cohort study from a single tertiary ILD centre. All patients commenced on AFT for IPF between 1 st October 2014 and 31 st December 2015 were identified. Patients were assessed at 12 months for adherence to treatment and weight loss. Statistical analysis was conducted using GraphPad software. ). In both 2016 (p=0.0119) and 2017 (p=0.0089), there were more patients on AFDs per postcode area where the local hospital was a PC compared to a NPC. Looking at the distribution of IMD in 2017, there was a small difference (p=0.057) that did not appear fully to explain the difference in AFD prescriptions between PC and NPC. Conclusions The NHS constitution requires equality in access to therapy regardless of where the patient lives. Although AFD prescriptions have increased significantly between 2016 and 2017, we have again demonstrated inequality of access to AFDs depending on patient location. These differences do not appear fully explained by differences in indices of multiple deprivation. Introduction Treatment of IPF with pirfenidone slows disease progression as measured by changes in forced vital capacity (FVC), independent of baseline FVC values. In a previous analysis of patients with limited vs more advanced lung function impairment, increases in University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) scores were more pronounced in patients with Gender Age Physiology index (GAP) stage II/III vs GAP stage I and in patients with baseline FVC <80% vs FVC !80%0
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EFFECT OF PIRFENIDONE ON BREATHLESSNESS AS MEASURED BY THE UCSD-SOBQ SCORE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) WITH MODERATE LUNG FUNCTION IMPAIRMENT
. 1 We examined the effect of pirfenidone on UCSD-SOBQ in these subpopulations. Methods 1247 patients in ASCEND (NCT01366209) and CAPACITY (NCT00287716; NCT00287729) were randomised to pirfenidone 2403 mg/d or placebo. Patients were stratified by GAP stage I vs stage II/III and by baseline%-predicted FVC. The effect of pirfenidone on UCSD-SOBQ score was assessed by continuous and categorical changes from baseline over 12 months, and by multiples of the minimal clinically important difference of 5 points for UCSD-SOBQ. Results Pirfenidone-treated patients with GAP stage II/III had higher UCSD-SOBQ scores after 12 months than those with GAP stage I (median increase from baseline: 9.4 vs 5.0); similar Results occurred with placebo (12.5 vs 4.3). GAP stage II/ III patients treated with pirfenidone had less increase in median UCSD-SOBQ score at 12 months compared with those receiving placebo (9.4 vs 12.5; median difference À3.5, 95% CI À6.2,-0.5; p=0.0161) with the curves diverging after 3 months (figure 1). Evaluation of categorical change for patients with GAP stage II/III demonstrated that pirfenidone reduced the proportion of patients with UCSD-SOBQ score increases of !15 points (45.6% vs 38.4%; p=0.0449) and !20 points (37.7% vs 28.6%; p=0.0089) at 12 months compared with placebo; increases of !5 or!10 points were similar between treatment groups. Results in patients with% FVC £80% were comparable to GAP stage II/III. Conclusions In patients with IPF with moderate lung function impairment, pirfenidone reduced the progression of breathlessness compared with placebo. Patients receiving pirfenidone showed less change from baseline in UCSD-SOBQ score and a lower proportion of patients had more pronounced increases in UCSD-SOBQ scores at 12 months. 
